Employer subsidy initiatives are reducing employee out-of-pocket costs for Zepbound KwikPen via GoodRx and Lilly’s direct platform, Elfun Trusts has trimmed its LLY stake by roughly 30%, and options volume is running at about 52.5% of average daily share turnover.

Mounjaro and Zepbound drove a 43% Q4 2025 revenue increase to $19.3 billion and together accounted for 56% of sales, underpinned by strong U.S. and international uptake. Management guided 2026 revenues of $80–83 billion (≈25% growth) and a post-R&D/SG&A margin ratio of 46–47.5%. Employer-access platforms and the upcoming oral GLP-1 orforglipron program are positioned to extend this growth trend.

Regulatory reforms and litigation overhang are creating uncertainty around pricing power and payor coverage for GLP-1 obesity and diabetes therapies, even as Eli Lilly builds controlled-access channels like Employer Connect, forges partnerships with benefit administrators and pharmacies, and expands manufacturing capacity in Pennsylvania under favourable tax and zoning incentives to meet strong demand amid intensifying competition and evolving reimbursement regimes.

Eli Lilly’s GLP-1 dominance and breadth of innovation underpin bullish investor expectations, offset by concerns over its lofty valuation and near-term pullbacks.